The economic burden of myalgic encephalomyelitis/chronic fatigue syndrome in Australia.
Zhao, Ting, Cox, Ingrid A, Ahmad, Hasnat et al. · Australian health review : a publication of the Australian Hospital Association · 2023 · DOI
Quick Summary
This study looked at how much money ME/CFS costs patients, their families, and Australia as a whole. Researchers surveyed 175 Australian patients and found that ME/CFS costs about $63,400 per person each year on average. Most of these costs come from lost work and productivity, plus care provided by family members, rather than from doctor visits and medicines. People with severe ME/CFS have much higher costs than those with milder forms.
Why It Matters
Understanding the true economic burden of ME/CFS is crucial for advocacy, healthcare policy, and securing research funding. This data demonstrates that ME/CFS costs Australia billions annually, primarily through lost productivity and informal care—insights that can help policymakers recognize ME/CFS as a serious public health issue warranting greater support and investment.
Observed Findings
Total annual societal costs per patient averaged $63,400 AUD (range: $1.38–$10.09 billion nationally).
Indirect costs (lost productivity and informal care) accounted for approximately 75% of total costs.
Disability severity was the strongest predictor of costs, with severe cases showing 2.27 times higher indirect costs than mild/no disability.
Participants were predominantly female (79.4%) with mean age 49 years.
Informal care by family members represented a substantial portion of unmeasured or underestimated costs.
Inferred Conclusions
ME/CFS imposes a substantial economic burden on Australian society, driven primarily by indirect costs rather than direct medical expenses.
Disability severity is the key factor determining economic impact, suggesting that disease severity correlates with broader life disruption beyond healthcare costs.
Informal care and productivity losses are underrecognized costs that dominate the overall economic picture and may be inadequately captured by conventional health system metrics.
The significant economic burden supports the case for greater research funding, better treatment options, and social support for patients with ME/CFS.
Remaining Questions
What This Study Does Not Prove
This study does not establish causation or compare costs to other chronic illnesses. The convenience sampling method means results may not represent all Australian ME/CFS patients, particularly those without internet access or energy to participate. The findings reflect costs at one point in time and may not capture long-term trends in healthcare expenses.
Tags
Symptom:Fatigue
Phenotype:Severe
Method Flag:Weak Case DefinitionNo ControlsExploratory Only